Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

Radford, 2015, Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma, N Engl J Med, 372, 1598, 10.1056/NEJMoa1408648 André, 2017, Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial, J Clin Oncol, 35, 1786, 10.1200/JCO.2016.68.6394 Gordon, 2013, Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496), J Clin Oncol, 31, 684, 10.1200/JCO.2012.43.4803 Johnson, 2016, Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma, N Engl J Med, 374, 2419, 10.1056/NEJMoa1510093 Connors, 2018, Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma, N Engl J Med, 378, 331, 10.1056/NEJMoa1708984 Moskowitz, 1999, Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma, J Clin Oncol, 17, 3776, 10.1200/JCO.1999.17.12.3776 Bartlett, 2007, Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804, Ann Oncol, 18, 1071, 10.1093/annonc/mdm090 Kuruvilla, 2006, Cancer, 106, 353, 10.1002/cncr.21587 Moskowitz, 2012, Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood, 119, 1665, 10.1182/blood-2011-10-388058 Younes, 2012, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol, 30, 2183, 10.1200/JCO.2011.38.0410 Gopal, 2015, Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma, Blood, 125, 1236, 10.1182/blood-2014-08-595801 Moskowitz, 2015, PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study, Lancet Oncol, 16, 284, 10.1016/S1470-2045(15)70013-6 LaCasce, 2018, Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma, Blood, 132, 40, 10.1182/blood-2017-11-815183 Garcia-Sanz, 2019, Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group), Ann Oncol, 30, 612, 10.1093/annonc/mdz009 Herrera, 2018, Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma, Blood, 131, 1183, 10.1182/blood-2017-10-811224 Stamatoullas, 2019, Brentuximab vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study, Blood, 134, 132, 10.1182/blood-2019-123925 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Panico, 2015, High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages, Leuk Lymphoma, 56, 1636, 10.3109/10428194.2014.951849 Asano, 2006, Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study, J Clin Oncol, 24, 4626, 10.1200/JCO.2006.06.5342 Steidl, 2010, Tumor-associated macrophages and survival in classic Hodgkin's lymphoma, N Engl J Med, 362, 875, 10.1056/NEJMoa0905680 Ravanpay, 2018, The first report of human primary thoracic spine mast cell sarcoma: a case report, Clin Neuropathol, 37, 28, 10.5414/NP301038 Wu, 2014, Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH, Clin Cancer Res, 20, 4540, 10.1158/1078-0432.CCR-13-3231 Sweetenham, 2015, Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in hodgkin lymphoma patients at high risk of relapse, Blood, 126, 10.1182/blood.V126.23.3172.3172 Moskowitz, 2018, Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse, Blood, 132, 2639, 10.1182/blood-2018-07-861641 Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618 Crump, 2014, Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12, J Clin Oncol, 32, 3490, 10.1200/JCO.2013.53.9593 Herrera, 2019, PET-Adapted nivolumab or nivolumab plus ICE as first salvage therapy in relapsed or refractory hodgkin lymphoma, Blood, 134, 239, 10.1182/blood-2019-123162 LaCasce, 2020, Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma, Br J Haematol, 189, e86, 10.1111/bjh.16499 Spina, 2018, Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma, Blood, 131, 2413, 10.1182/blood-2017-11-812073